# Molina Healthcare, Inc.: Form 10-Q for the period ended Sep 30, 2024

- Company: [Molina Healthcare, Inc.](/companies/moh.md) (CIK 1179929)
- Form: 10-Q
- Filed: 2024-10-24
- Accepted by EDGAR: Oct 24, 2024, 10:34 ET
- Period: 2024-09-30
- Accession: 0001179929-24-000151
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1179929/000117992924000151/moh-20240930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1179929/000117992924000151/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2024-07-01 to 2024-09-30 | $10.34bn | us-gaap:Revenues |
| Revenue | 9 months, 2024-01-01 to 2024-09-30 | $30.15bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2024-07-01 to 2024-09-30 | $8.64bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2024-01-01 to 2024-09-30 | $25.43bn | us-gaap:CostOfGoodsAndServicesSold |
| Operating income | 3 months, 2024-07-01 to 2024-09-30 | $467.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2024-01-01 to 2024-09-30 | $1.33bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2024-07-01 to 2024-09-30 | $29.0m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months, 2024-01-01 to 2024-09-30 | $84.0m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months, 2024-07-01 to 2024-09-30 | $112.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2024-01-01 to 2024-09-30 | $315.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-07-01 to 2024-09-30 | $326.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2024-01-01 to 2024-09-30 | $928.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-07-01 to 2024-09-30 | $5.65 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2024-01-01 to 2024-09-30 | $15.97 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-07-01 to 2024-09-30 | $5.67 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2024-01-01 to 2024-09-30 | $16.05 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-07-01 to 2024-09-30 | 57,700,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2024-01-01 to 2024-09-30 | 58,100,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2024-01-01 to 2024-09-30 | $868.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2024-01-01 to 2024-09-30 | $89.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2024-01-01 to 2024-09-30 | $500.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2024-09-30 | $4.73bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-09-30 | $12.88bn | us-gaap:AssetsCurrent |
| Total assets | at 2024-09-30 | $15.76bn | us-gaap:Assets |
| Current liabilities | at 2024-09-30 | $8.34bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-09-30 | $10.99bn | us-gaap:Liabilities |
| Long-term debt | at 2024-09-30 | $2.33bn | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2024-09-30 | $4.77bn | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1179929/000117992924000151/moh-20240930.htm

Filed Oct 24, 2024.
Source: SEC EDGAR, the filing index for accession 0001179929-24-000151. Last ingested by Listed: Nov 15, 2026, 00:39 ET. No prices; not investment advice.
